Companies: 10,795·Total market cap: $144.5T

NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V.

NAMSNASDAQHealthcare● Active

$31.21

$-0.31(-0.97%)

Market Cap$3.6B

P/E Ratio—

52W High$42.205

52W Low$17.63

Avg Volume1.2M

Open$31.86

Beta0.08

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

NewAmsterdam Pharma Company N.V.（NAMS）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · NAMS · 截至 Jun 8, 2026

关键指标

EPS (TTM)$-1.81Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$22.6MFull revenue history

Dividend Yield不分红Dividend history

Shares Outstanding114.4MShares outstanding history

Next EarningsAug 5, 2026Est.Earnings history

探索 NewAmsterdam Pharma Company N.V. 数据

分析师预测$49 · Buy

股息不分红

营收$22.5M-50.61%

盈利EPS $-1.75+31.64%

财务快照

FY 2025Revenue$22.5M▼ 50.61% YoY

202320242025

FY 2025Net Income-$203.8M▲ +15.64% YoY

202320242025

FY 2025EPS$-1.75▲ +31.64% YoY

202320242025

TTM:Revenue: $22.6MNet Income: -$212.7MEPS: $-1.81View income statement →

分析师评级与目标价

Buy10 位分析师

Strong Buy

0

Buy

9

Hold

1

Sell

0

Strong Sell

0

12-Month Price Target

$45.00Low

$31.21Current

$49.00Avg Target上涨空间 56.98%

$55.00High

合计: 10 · 买入占比: 90.0%

根据过去 3 个月内 10 位华尔街分析师，NAMS 共识评级为 Buy，12 个月平均目标价 $49.00 （较现价 $31.21 上涨空间 56.98%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

NewAmsterdam Pharma Company N.V.

$31.21-0.97%$3.6B #2

$115.07+0.02%$6.7B #3

Akero Therapeutics, Inc.

$54.65+0.00%$4.5B #4

CG Oncology, Inc. Common stock

$54.15+0.89%$4.8B #5

Crinetics Pharmaceuticals, Inc.

$33.47+1.92%$3.5B #6

Immunovant, Inc.

$30.87-0.84%$6.3B

股票表现

1D-0.97%

1W-1.50%

1M-19.40%

3M+4.54%

YTD-11.02%

1Y+54.83%

5Y+218.52%

关于 NewAmsterdam Pharma Company N.V.

CEOMichael Harvey Davidson Facp.

IPO DateFeb 9, 2021

Employees68

CountryUS

Websitenewamsterdampharma.com

NewAmsterdam Pharma Company N.V. a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib,…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

NewAmsterdam Pharma Company N.V.（NAMS）是 Biotechnology 行业的 Healthcare 类公司，于 Feb 9, 2021 在 NASDAQ 上市。截至最近交易日，NAMS 股价为 $31.21，市值约为 $3.6B。过去12个月累计回报 +54.83%，年初至今回报 -11.02%。

根据 10 位华尔街分析师，NewAmsterdam Pharma Company N.V. 股票共识评级为Buy，12个月平均目标价为 $49.00。2025 财年 NewAmsterdam Pharma Company N.V. 营收 $22.5M，净利润 -$203.8M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，NewAmsterdam Pharma Company N.V.（NAMS）股价为 $31.21，在 NASDAQ 上市，52周区间为 $17.63 – $42.20。

NAMS 最新股价NAMS quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 8, 2026本内容不构成投资建议